Immunic (NASDAQ:IMUX) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a research report report published on Thursday morning.

Several other research firms also recently weighed in on IMUX. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Immunic in a research note on Friday, February 21st. D. Boral Capital restated a “buy” rating and set a $17.00 price objective on shares of Immunic in a report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Immunic has an average rating of “Buy” and a consensus target price of $12.67.

Immunic Trading Up 0.9 %

NASDAQ IMUX opened at $1.15 on Thursday. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11. The company’s 50-day moving average price is $1.06 and its 200-day moving average price is $1.22. The stock has a market cap of $103.59 million, a PE ratio of -0.93 and a beta of 1.89.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares in the last quarter. State Street Corp raised its position in Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Jane Street Group LLC lifted its position in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the period. Virtu Financial LLC acquired a new position in shares of Immunic in the 3rd quarter valued at about $50,000. Finally, HB Wealth Management LLC purchased a new stake in shares of Immunic in the fourth quarter worth about $81,000. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.